Anti-MAP3K14 Antibody, clone 2M16 ZooMAb^® Rabbit Monoclonal

Mitogen-activated protein kinase kinase kinase 14 (UniProt: Q99558; also known as NF-kappa-beta-inducing kinase, NFkB inducing Kinase, HsNIK, Serine/threonine-protein kinase NIK, EC:2.7.11.25) is encoded by the MAP3K14 (also known as NIK) gene (Gene ID: 9020) in human. NF-kB is a ubiquitous transcription factor and an essential mediator of gene expression during activation of immune and inflammatory responses. It shares sequence similarity with several other MAPKK kinases. This kinase binds to TRAF2 and stimulates NF-kappaB activity. NF-kB mediates the expression of a great variety of genes in response to extracellular stimuli including IL-1, TNFalpha, LPS and mitogens. MAP3K14 is an activator of IkB kinase alpha and beta (IKKalpha and IKKbeta). It plays a pivotal role in cellular signaling pathways, particularly in the non-canonical NF-kB signaling cascade. MAP3K14 is weakly expressed in testis, small intestine, spleen, thymus, peripheral blood leukocytes, prostate, ovary and colon. It′s expression is notably upregulated in various cancerous tissues. Structurally, MAP3K14 consists of a protein kinase domain that facilitates its interaction with various substrates, leading to the activation of downstream signaling pathways. It is predominantly localized in the cytoplasm but can translocate to the nucleus in response to specific stimuli, such as inflammatory signals. Notably, its expression is linked to the development of hepatocellular carcinoma (HCC) in the context of chronic hepatitis B virus infection, where genetic variants of MAP3K14 have been identified as potential prognostic markers for patient survival. Dysregulation of MAP3K14 is implicated in several diseases, including cancers, autoimmune disorders, and viral infections, highlighting its significance as a therapeutic target. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Tang, K., et al. (2024). Cancer. 15(9); 2731-2745; Aoki, Y., et al. (2023). Immunologic Research. (71); 814-832).

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

KLH-conjugated linear peptide corresponding to 25 amino acids from the N-terminal half of human MAP3K14.

Quality Control Testing

Evaluated by Western Blotting in A549 cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected MAP3K14 in A549 cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected MAP3K14 in lysate from HT-1080 cells treated with MG-132 (10 µM, 4 hours).

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected MAP3K14 in human pancreas tissue sections.

Immunocytochemistry Analysis: A 1:1,000 dilution from a representative lot detected MAP3K14 in A549 cells.

Affinity Binding Assay: A representative lot of this antibody bound MAP3K14 peptide with at least one billion-fold (1,000,000,000X) higher affinity than with non-specific control peptide.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 2M16 is a ZooMAb^® recombinant rabbit monoclonal antibody that specifically detects MAP3K14. It targets an epitope within 25 amino acids from the N-terminal half.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.